Late delayed adjuvant tamoxifen in early breast cancer. Results of a cooperative randomized trial;Tamoxifene adjuvant retarde dans le cancer du sein curable. Resultats d'un essai cooperatif randomise

Bulletin du Cancer

Volumn 84, Issue 1, 1997, Pages 25-30

  Delozier, Thierry ^a   Switsers, Odile ^a   Génot, Jean Yves ^a   Ollivier, Jean Michel ^a   Héry, Michel ^b   Namer, Moïse ^b   Frenay, Marc ^b   Kerbrat, Pierre ^c   Julien, Jean Pierre ^d   Naja, Adnan ^e   Janvier, Maud ^f   Macé Lesec'h, Josette ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f CENTRE RENÉ HUGUENIN   (France)

Author keywords

adjuvant treatment; breast cancer; tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; DRUG ADMINISTRATION; FRANCE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0030634354     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Bonadonna G, Brusamolino E, Valagusa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-10.
2. Brinkley D, Haybittle JL. Long term survival of women with breast cancer. Lancet 1984; 311: 1118.
3. EBCTCG. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, Worldwide evidence 1985-1990. Vol. 1. Oxford: Oxford University Press, 1990.
4. EBCTCG. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992a; 339: 1-15.
5. EBCTCG. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992b; 339: 71-85.
6. Fischer B, Carbone P, Economous S. L-phenalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 1975; 292: 117-21.